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The perceived health status of individuals with severe
psychiatric illness, such as schizophrenia, is an important
element of disease burden and quality of life. The effect
of antipsychotic therapies on psychiatric symptoms is
well-understood. However, more information about the
effects of antipsychotics on health status is needed. OB-
JECTIVE: To examine changes in health-related quality
of life (HRQL) from inpatient admission to follow-up of
adult and geriatric patients with schizophrenia treated
with conventional or atypical antipsychotic agents.
METHODS: Data were obtained from the CQISM Out-
comes Measurement System, an ORYX (JCAHO) ac-
cepted performance improvement system, which tracks
patients admitted to adult or geropsychiatric inpatient
programs in over 100 general hospitals across 35 states.
Health status was measured by the SF-36 at time of ad-
mission and at three (geriatric) or six months (adult)
post-discharge. Patients with a primary discharge diagno-
sis of schizophrenia (ICD-9-CM codes 295.10–295.90)
who completed the SF-36 and were treated with antipsy-
chotic agents were included. One sample t-tests were
used to test the null hypothesis that the mean change is
equal to zero. RESULTS: Mean scores were higher (i.e.,
healthier) at follow-up, as compared to admission, on all
eight domains of the SF-36 for the adult schizophrenic
group (n  37) and seven of eight domains for the geriat-
ric schizophrenic group (n  38). Statistically significant
improvements were noted on five of the eight scales.
Largest improvements were found on Role Physical (P 
0.001), Role Emotional (P  0.001), and Social Func-
tioning (P  0.001). CONCLUSIONS: Marked improve-
ment in diverse aspects of HRQL among schizophrenic
patients treated with conventional or atypical antipsy-
chotic agents supports the humanistic value of antipsy-
chotic medications beyond simple symptom ameliora-
tion.
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OBJECTIVE: To describe the effect of depression on
health-related quality of life (HRQL) utilizing the SF-36
health status survey. The scores of patients with depres-
sion were compared to age and gender matched US popu-
lation norms and contrasted to results of similar research
on patients with other psychiatric disorders. METHODS:
SF-36 scores were collected from patients admitted to
adult (n  600) or geriatric (n  4439) psychiatric pro-
grams within acute care hospitals who had an ICD-9-CM
discharge diagnosis of depressive disorder. Adult and ge-
riatric US population norms were simulated using data
from the Medical Outcomes Study Manual and Interpre-
tation Guide to match the age and gender distributions of
the adult and geriatric depression groups. Admission SF-36
scores for the adult and geriatric depression groups were
compared to these age and gender matched US popula-
tion norms using independent sample t-tests. The find-
ings were then placed in context of SF-36 scores for other
psychiatric conditions including schizophrenia, bipolar
disorder, and cognitive disorder. RESULTS: HRQL for
both the adult and geriatric groups of depressed patients
was significantly lower than the simulated US population
norms for all eight domains of the SF-36, for physical
health as well as mental health (P  0.001). The greatest
differences were observed in the Role Physical, Social
Functioning, and Role Emotional domains. Adult inpa-
tients with depression had similar scores on all domains
to adult patients with the other psychiatric diagnoses
studied. However, geriatric patients with depression had
lower scores on HRQL across all domains versus geriat-
ric patients with other psychiatric illnesses. CONCLU-
SIONS: Depression has a strong negative association
with both adult and geriatric patients’ perceived HRQL.
Depressed patients not only had the expected decreases
on mental health domains, but also scored significantly
lower on physical health domains. Finally, depression in
geriatric patients is associated with greater decrements in
HRQL than other psychiatric illnesses examined.
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Currently there are no published studies comparing the
health-related quality of life (HRQoL) of transformed
and episodic migraneurs. OBJECTIVES: The study objec-
tive was to detect differences in HRQoL between patients
with transformed migraine (TM) and episodic migraine
(EM). METHODS: This retrospective study examined
the HRQoL of transformed and episodic migraneurs of
the Jefferson Headache Center during their first visit to
the center. Data collected included the Short Form 36
(SF-36) and the Migraine Disability Assessment (MIDAS)
questionnaires as well as demographic information. A
t-test with Bonferroni correction was used to test for sig-
nificant differences in the SF-36 domains between the
groups. RESULTS: To date, data has been collected on
62 patients, 31 from each group. There were no signifi-
cant differences with respect to gender, race, age or the
number of comorbid conditions between groups. Over
the last 90 days prior to their first visit, patients with TM
reported having a headache on an average of 77 days
compared to EM patients who averaged 18 days with
headache (P  0.05). Compared to EM patients, patients
with TM had statistically and clinically significant (5
point difference) lower mean scores on the mental com-
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ponent summary score as well as on the general health,
vitality, social functioning and role emotional domains of
the SF-36 (P  0.05). CONCLUSIONS: The results of
this interim analysis suggest that TM patients have a
lower quality of life than patients with EM.
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Patients who received at least one abortive migraine pre-
scription during July 1998 through December 1998 and
who had been continuously enrolled in a large west coast
health maintenance organization (HMO) for that period
were identified through the HMO pharmacy prescription
database and screened for eligibility criteria. Eligible
HMO patients were those who did not have any sensitiv-
ity nor contraindications to receiving Excedrin-migraine.
Patients from four medical groups in Southern California
were asked to participate based on the groups’ higher
than network migraine prescription utilization. Physician
groups who participated in the program consisted mainly
of primary care physicians or family practitioners and a
small proportion of neurologists. OBJECTIVE: To evalu-
ate the effects of an over-the-counter (OTC) migraine
medication on patient quality-of-life two and four months
after initiation therapy. METHODS: This was an obser-
vational study where enrolled patients received a one
month supply of Excedrin-migraine samples along with a
self-administered SF-36 questionnaire to complete at
baseline, months two and four. All data were analyzed
using SAS statistical software (version 6.12) with  set at
0.05. RESULTS: Results at month four indicated im-
provements in both MCS (P  0.05) and PCS scores. In
addition, there were improvements in seven of the eight
domains of the SF-36 with Role Physical, Bodily Pain, Vi-
tality and Social Functioning being significantly different
(P  0.05). CONCLUSION: In the four months after ini-
tiation of the OTC migraine program, quality-of-life
scores improved for the migraineurs enrolled in the
study.
PMH30
MODELING LENGTH OF PRESCRIPTION 
THERAPY FOR DEPRESSION PATIENTS
Billingsley J-K, Nichols JL
IMS Health, Plymouth Meeting, PA, USA
Length of therapy can affect clinical outcomes as well as
total healthcare costs that patients incur. Understanding
which factors influence length of therapy can be a major
step in managing treatment. OBJECTIVE: To identify
factors affecting length of antidepressant pharmacother-
apy for depression patients. METHODS: Using an em-
ployer claims database, antidepressant prescription claims
of 2,830 depression patients were analyzed for 18
months following their initial prescription for a SSRI/
SNRI, Newer Generation Antidepressant, or Tricyclic/
Tetracyclic in 1996. A wide range of demographic, pa-
tient- and prescription-level data were reviewed. Linear
regression modeling was implemented to model length of
antidepressant pharmacotherapy as a function of explan-
atory variables. RESULTS: The linear regression model
estimated length of prescription therapy as f (age, physi-
cian specialty prescribing medication, number of unique
drugs prescribed, starting drug therapy class, switch in
drug therapy class [yes/no], and number of gaps in ther-
apy). The model was significant (P  0.05) overall, as
was each regressor. Based on findings, the following in-
ferences can be made: (1) older patients underwent
longer therapy; (2) patients treated by a psychologist/
neurologist or both a primary care physician and a psy-
chologist/neurologist underwent longer therapy than pa-
tients treated by primary care physicians exclusively; pa-
tients treated by other physician specialties underwent
shorter therapy; (3) each additional, unique drug pre-
scribed resulted in longer total therapy; (4) patients ini-
tially treated with SSRIs/SNRIs had longer therapy than
patients initially treated with other antidepressant cate-
gories; and (5) each additional gap in therapy resulted in
progressively longer therapy. CONCLUSION: A positive
relationship was observed between the length of patient’s
antidepressant pharmacotherapy and a number of fac-
tors. A thorough understanding and management of
these factors could lead to improved patient outcomes.
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OBJECTIVE: To assess the treatment of childhood de-
pression in a managed care population. METHODS: All
subjects contained within Pharmetric’s Integrated Out-
comes database possessing a diagnosis of depression
(ICD-9-CM  296.2, 296.3, 300.4, 311) during 1997–98,
who were between 6–18 years of age at the time of diag-
nosis and were continuously enrolled for more than 1
year, were eligible for study inclusion. Utilization of psy-
chotherapy and pharmacotherapy during the 1-year pe-
riod following initial diagnosis was measured, as was de-
pression-related hospitalization. These measures were
compared across age categories (6–14, 15–18) and gen-
der, and hospitalization rates were compared across psy-
chotherapy and pharmacotherapy cohorts. RESULTS:
461 patients met the inclusion criteria. The mean age was
15.4 years and 51.4% of the sample was female. 96.5%
of patients received some type of pharmacotherapy,
while only 214 (46.4%) subjects received psychotherapy.
